Uremic toxicity and sclerostin in chronic kidney disease patients

Nephrologie et Therapeutique

Volumn 10, Issue 6, 2014, Pages 463-470

  Desjardins, Lucie ^a,b   Liabeuf, Sophie ^a,b   Oliveira, Rodriguo B ^a   Louvet, Loïc ^a   Kamel, Saïd ^a   Lemke, Horst Dieter ^c   Vanholder, Raymond ^d   Choukroun, Gabriel ^a,b   Massy, Ziad A ^a,e  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c eXcorLab GmbH   (Germany)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Chronic kidney disease; Mortality; Sclerostin; Uremic toxins

Indexed keywords

4 CRESYL SULPHATE; BETA 2 MICROGLOBULIN; FIBROBLAST GROWTH FACTOR 23; INDICAN; INTERLEUKIN 6; PHOSPHATE; SCLEROSTIN; UNCLASSIFIED DRUG; UREMIC TOXIN; 4-CRESOL SULFATE; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; CRESOL; FIBROBLAST GROWTH FACTOR; GENETIC MARKER; SOST PROTEIN, HUMAN; SULFATE;

AGE; AGED; ARTERIAL STIFFNESS; ARTICLE; CHRONIC KIDNEY DISEASE; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; SCORING SYSTEM; TOXICITY; UREMIC TOXICITY; VASCULAR DISEASE; ADULT; AORTOGRAPHY; ARTERIOSCLEROSIS; BLOOD; CALCINOSIS; CHRONIC KIDNEY FAILURE; COMPLICATION; DIAGNOSTIC IMAGING; FOLLOW UP; GENETIC MARKER; INFLAMMATION; MIDDLE AGED; PATHOPHYSIOLOGY; PULSE WAVE; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SURVIVAL ANALYSIS; UREMIA;

ADULT; AGED; AORTOGRAPHY; ARTERIOSCLEROSIS; BETA 2-MICROGLOBULIN; BIOMARKERS; BONE MORPHOGENETIC PROTEINS; CALCINOSIS; CRESOLS; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; GENETIC MARKERS; HUMANS; INDICAN; INFLAMMATION; MALE; MIDDLE AGED; PULSE WAVE ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; SULFURIC ACID ESTERS; SURVIVAL ANALYSIS; TOMOGRAPHY, SPIRAL COMPUTED; UREMIA; VASCULAR STIFFNESS;

EID: 84922803328     PISSN: 17697255     EISSN: 18729177     Source Type: Journal    
DOI: 10.1016/j.nephro.2014.04.002     Document Type: Article

References (45)

1. Baron R, Rawadi G. Targeting the Wnt/b-Catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007;148:2635-43.
2. Paszty C, Turner CH, Robinson MK. Sclerostin: a gem from the genome leads to bone-building antibodies. J Bone Miner Res 2010;25:1897-904.
3. Ten Dijke P, Krause C, de Gorter DJJ, Löwik CWGM, van Bezooijen RL. Osteo-cyte-derived sclerostin inhibits bone formation: its role in bone morphoge-netic protein and Wnt signaling. J Bone Joint Surg Am 2008;90(Suppl. 1):31-5.
4. Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, et al. Characterization of the structural features and interactions of sclerostin. J Biol Chem 2009;284:10890-900.
5. Balemans W, Ebeling M, Patel N, Hul EV, Olson P, Dioszegi M, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001;10:537-43.
6. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001;68:577-89.
7. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008;23:860-9.
8. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26.
9. Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011;6:877-82.
10. Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, et al. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 2012;90:473-80.
11. Sabbagh Y, Graciolli FG, O'Brien S, Tang W, dos Reis LM, Ryan S, et al. Repression of osteocyte Wnt/b-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 2012;27:1757-72.
12. Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 2013;8:819-23.
13. Cejka D, Jäger-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2012;27:226-30.
14. Niwa T. Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr 2010;20:S2-6.
15. Meijers BKI, Van kerckhoven Soetkin, Verbeke K, Dehaen W, Vanrenterghem Y, Hoylaerts MF, et al. The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 2009;54:891-901.
16. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009;4:1551-8.
17. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010;25:1183-91.
18. Barreto FC, Barreto DV, Liabeuf S, Drüeke TB, Massy ZA. Effects of uremic toxins on vascular and bone remodeling. Semin Dial 2009;22:433-7.
19. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
20. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemo-dialysis. N Engl J Med 2008;359:584-92.
21. Meert N, Eloot S, Waterloos MA, Landschoot MV, Dhondt A, Glorieux G, et al. Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant 2009;24:562-70.
22. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008;51:395-406.
23. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-201.
24. Zureik M, Temmar M, Adamopoulos C, Bureau JM, Courbon D, Thomas F, et al. Carotid plaques, but not common carotid intima-media thickness, are independently associated with aortic stiffness. J Hypertens 2002;20: 85-93.
25. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995;26:485-90.
26. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify location, severity and progression of calcific lesions in the abdomi-nal aorta: a 25-year follow-up study. Atherosclerosis 1997;132:245-50.
27. Rosenbaum PR, Rubin DB. The central role of the propensity score in observa-tional studies for causal effects. Biometrika 1983;70:41-55.
28. Morales-Santana S, García-Fontana B, García-Martín A, Rozas-Moreno P, García- Salcedo JA, Reyes-García R, et al. Atherosclerotic disease in type 2 Diabetes is associated with an increase of sclerostin levels. Diabetes Care 2013;36: 1667-1674.
29. van Lierop AH, Witteveen JE, Hamdy NT, Papapoulos SE. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than eupara-thyroid controls. Eur J Endocrinol 2010;163:833-7.
30. Claes KJ, Viaene L, Heye S, Meijers B, d'Haese P, Evenepoel P. Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab 2013;98:3221-8.
31. Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, et al. Sclero-stin: another bone-related protein related to all-cause mortality in haemo-dialysis? Nephrol Dial Transplant 2013;28:3024-30.
32. Goto S, Yoshiya K, Kita T, Fujii H, Fukagawa M. Uremic toxins and oral adsorbents. Ther Apher Dial 2011;15:132-4.
33. Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Hosokawa A, et al. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant 2006;21:2768-74.
34. Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N. A multi-center, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006;47:565-77.
35. Vincent C, Findlay DM, Welldon KJ, Wijenayaka AR, Zheng TS, Haynes DR, et al. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFa induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 2009;24:1434-49.
36. Kim BJ, Bae SJ, Lee SY, Lee YS, Baek JE, Park SY, et al. TNF-a mediates the stimulation of sclerostin expression in an estrogen-deficient condition. Bio-chem Biophys Res Commun 2012;424:170-5.
37. Ryan ZC, Ketha H, McNulty MS, McGee-Lawrence M, Craig TA, Grande JP, et al. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci U S A 2013;110:6199-204.
38. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005;115:1210-20.
39. Szulc P, Bertholon C, Borel O, Marchand F, Chapurlat R. Lower fracture risk in older men with higher sclerostin concentration - A prospective analysis from the MINOS study. J Bone Miner Res 2012;28(4):855-64.
40. Craig TA, Bhattacharya R, Mukhopadhyay D, Kumar R. Sclerostin binds and regulates the activity of cysteine-rich protein 61. Biochem Biophys Res Com-mun 2010;392:36-40.
41. Kokubo H, Miyagawa-Tomita S, Nakashima Y, Kume T, Yoshizumi M, Nakanishi T, et al. Hesr2 Knockout mice develop aortic valve disease with advancing age. Arterioscler Thromb Vasc Biol 2013;33:e84-92.
42. Liabeuf S, Lenglet A, Desjardins L, Neirynck N, Glorieux G, Lemke HD, et al. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int 2012;82:1297-303.
43. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2011;26:938-47.
44. Meijers BKI, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K, et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010;5:1182-9.
45. Oliveira RB, Graciolli FG, Dos Reis LM, Cancela L, Canziani ME, Carvalho AB, et al. Disturbances of Wnt/b-catenin pathway and energy metabolism in early CKD: effect of phosphate binders. Nephrol Dial Transplant 2013;28:2510-7.